Researchers suggest that a simple explanation of the benefits and harms of a medication could improve a patient’s drug of choice, according to a Dartmouth College release. Previous research suggests ...
Structure Therapeutics Inc. (GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024. This is an ...
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...
Hosted on MSN
The one, big unanswered question about Ozempic
This story was originally published in The Highlight, Vox’s member-exclusive magazine. To get early access to member-exclusive stories every month, join the Vox Membership program today. We are ...
ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung ...
Small (left) and large (right) condensates of the Mediator complex inside nuclei of a pancreatic beta cell-derived cell line. Salk researchers discovered that GLP-1s interact with the multi-protein ...
Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Diabetes, Obesity), ...
TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results